Slc6A3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Solute Carrier Family 6 Member 3 (Dopamine Transporter)
| Property | Value |
|---------|-------|
| **Symbol** | SLC6A3 (DAT1) |
| **Full Name** | Solute Carrier Family 6 Member 3 |
| **Chromosomal Location** | 5p15.33 |
| **NCBI Gene ID** | 6531 |
| **OMIM** | 185520 |
| **Ensembl ID** | ENSG00000114190 |
| **UniProt** | Q01959 |
| **Associated Diseases** | Parkinson's Disease (PD), Dopamine Transporter Deficiency Syndrome (DTDS), ADHD, Bipolar Disorder |
SLC6A3 encodes the dopamine transporter (DAT), also known as DAT1, a membrane protein that reuptakes dopamine from the synaptic cleft back into presynaptic neurons. DAT is essential for terminating dopaminergic neurotransmission and maintaining dopamine homeostasis. It is a critical player in Parkinson's disease and other dopamine-related disorders.
The dopamine transporter functions in:
- Dopamine Reuptake: Transports dopamine from synaptic cleft back into presynaptic terminal
- Synaptic Clearance: Terminates dopamine signaling after release
- Dopamine Homeostasis: Maintains intracellular dopamine pools
- Neuroprotection: Prevents extracellular dopamine accumulation and oxidative stress
DAT is a member of the Na+/Cl- dependent neurotransmitter transporter family. It couples dopamine transport to Na+ and Cl- gradients, using the energy from these ion gradients to drive uptake.
DAT is central to PD pathophysiology:
- DAT Imaging: DaTscan (I-123 ioflupane SPECT) uses DAT binding to visualize dopaminergic neuron loss
- DAT Deficiency: Early PD shows reduced DAT binding in striatum
- Presynaptic Marker: DAT levels correlate with surviving dopaminergic neurons
A rare pediatric neurodegenerative disorder caused by SLC6A3 mutations:
- Infantile Parkinsonism: Presents in first year of life
- Progressive Movement Disorder: GTP cyclohydrolase I deficiency can be misdiagnosed as cerebral palsy
- Treatment: Tyrosine, tetrahydrobiopterin, and dopamine agonists
¶ ADHD and Neuropsychiatric Disorders
- Variable Repeat Polymorphism: 40-bp VNTR in 3' UTR affects DAT expression
- Association Studies: Links to ADHD, bipolar disorder, and substance abuse
DAT is expressed primarily in:
- Substantia Nigra Pars Compacta (SNpc): Dopaminergic cell bodies
- Striatum: Terminal fields (caudate, putamen)
- Ventral Tegmental Area (VTA): Mesolimbic and mesocortical projections
- ** olfactory bulb**
- DaTscan: FDA-approved SPECT imaging using I-123 ioflupane
- DAT PET: F-18 fluoroethyl-L-tyrosine (FET) and other PET tracers
- Early Detection: DAT imaging can detect presynaptic deficits before symptom onset
- DAT Inhibitors: Methylphenidate (Ritalin) for ADHD - increases dopamine availability
- DAT Blockers: Cocaine and amphetamines - abused substances that target DAT
- Neuroprotective Strategies: Maintaining DAT function in PD
- Borgelt L, et al. (2019). Dopamine transporter deficiency syndrome: Clinical spectrum and management. JIMD Rep.[1]
- Ziebell M, et al. (2015). DaTscan in Parkinson's disease: A quantitative review. Acta Neurol Scand.[2]
The study of Slc6A3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Borgelt L, et al. Dopamine transporter deficiency syndrome: Clinical spectrum and management. JIMD Reports 2019;45(1):21-30.
- Ziebell M, et al. DaTscan in Parkinson's disease: A quantitative review. Acta Neurologica Scandinavica 2015;131(4):221-231.